Preclinical Programs
Neurodegeneration (e.g., Alzheimer's, Parkinson's) and Pain
Key Facts
About iQure Pharma
iQure Pharma is a private, clinical-stage biotech founded in 2018 and headquartered in Cambridge, Massachusetts. The company is pioneering a novel neuroprotective strategy by developing small molecules that enhance the function of the EAAT2 glutamate transporter on astrocytes, aiming to treat a broad range of CNS disorders rooted in excitotoxicity. With its lead program, iQ-007, in a Phase 1 trial for epilepsy, the company is validating its platform and expanding into preclinical programs for neurodegeneration and pain. iQure leverages strong academic collaborations and is backed by venture capital investors.
View full company profileAbout MRM Health
MRM Health is a Belgian clinical-stage biotech pioneering a novel approach to live biotherapeutic products (LBPs) through its disruptive CORAL® platform. This technology enables the rational design and scalable manufacturing of optimized, disease-focused microbial consortia, aiming for superior efficacy and safety. The company has demonstrated clinical proof-of-concept in IBD, is advancing a pipeline in other inflammatory and immuno-oncology indications, and is backed by a strong syndicate of strategic and financial investors. Its end-to-end capabilities and academic partnerships position it as a key player in the evolving microbiome therapeutics field.
View full company profileAbout MRM Health
MRM Health is a Belgian clinical-stage biotech pioneering a novel approach to live biotherapeutic products (LBPs) through its disruptive CORAL® platform. This technology enables the rational design and scalable manufacturing of optimized, disease-focused microbial consortia, aiming for superior efficacy and safety. The company has demonstrated clinical proof-of-concept in IBD, is advancing a pipeline in other inflammatory and immuno-oncology indications, and is backed by a strong syndicate of strategic and financial investors. Its end-to-end capabilities and academic partnerships position it as a key player in the evolving microbiome therapeutics field.
View full company profileAbout Aramis Biosciences
Aramis Biosciences is a private, clinical-stage biotech targeting the significant unmet need in ocular surface diseases, particularly dry eye disease (DED). The company's approach is rooted in foundational research from Harvard Medical School's Schepens Eye Research Institute, focusing on modulating specific pro-inflammatory T helper cells implicated in DED pathogenesis. Its lead asset, A197, has completed enrollment in a Phase II proof-of-concept trial, with topline data expected in Q1 2023. Aramis is backed by a team of seasoned pharmaceutical executives and renowned scientific advisors, supported by strategic investors like Santen Ventures and Safar Partners.
View full company profile